|
Ruiz-Lorente I, Gimeno L, Lopez-Abad A, Lopez Cubillana P, Fernandez Aparicio T, Asensio Egea LJ, Moreno Aviles J, Donate Iniguez G, Guzman Martinez-Valls PL, Server G, Ferri B, Campillo JA, Martinez-Sanchez MV, Minguela A. Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with M. bovis BCG or Other Therapies. Biomedicines. 2025 Jan 10;13(1):156. doi: 10.3390/biomedicines13010156. PubMed PMID: 39857739; PubMed Central PMCID: PMC11760850.
AÑO: 2025; IF: 3.9
|
39857739
|
Pons-Fuster E, Martinez-Rodriguez R, Gimeno-Arias L, Alcaraz MJ, Moreno M, Gomez JM, Pelaez A, Garcia E, Tomas C, Munoz A, Martinez-Sanchez MV, Ruiz-Lorente I, Ceballos D, Minguela A, Bernal E. HLA-A*03 may confer protection against long COVID through an enhanced immune response. Infect Dis Now. 2025 Mar 17:105057. doi: 10.1016/j.idnow.2025.105057. Online ahead of print. PubMed PMID: 40107360.
AÑO: 2025; IF: 2.2
|
|
Ruiz-Lorente I, Gimeno L, Lopez-Abad A, Cubillana PL, Aparicio TF, Egea LJA, Aviles JM, Iniguez GD, Martinez-Valls PLG, Server G, Ferri B, Campillo JA, Galindo F, Martinez-Sanchez MV, Minguela A. HLA class-I genotyping to personalize Bacille Calmette-Guerin immunotherapy in bladder cancer. Oncoimmunology. 2025 Dec 31;14(1):2598920. doi: 10.1080/2162402X.2025.2598920. Epub 2025 Dec 12. PubMed PMID: 41384865; PubMed Central PMCID: PMC12710922.
AÑO: 2025; IF: 6.3
|
|
Ruiz-Lorente I, Gimeno L, Lopez-Abad A, Lopez Cubillana P, Fernandez Aparicio T, Jesus Asensio Egea L, Moreno Aviles J, Donate Iniguez G, Guzman Martinez-Valls PL, Server G, Ferri B, Campillo JA, Galindo F, Boix F, Martinez-Sanchez MV, Martinez-Hernandez MD, Minguela A. Interplay of KIR2DL5, nitric oxide, and tobacco smoking in predisposition to bladder cancer. Front Cell Dev Biol. 2025 Sep 4;13:1632101. doi: 10.3389/fcell.2025.1632101. eCollection 2025. PubMed PMID: 40977889; PubMed Central PMCID: PMC12443833.
AÑO: 2025; IF: 4.3
|
|
Ramos Elbal E, Fuster JL, Campillo JA, Galera AM, Cortes MB, Llinares ME, Jimenez I, Plaza M, Martinez Banaclocha H, Galian JA, Blanquer Blanquer M, Martinez Sanchez MV, Muro M, Minguela A. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia. Clin Transl Oncol. 2024 Jan;26(1):278-287. doi: 10.1007/s12094-023-03251-0. Epub 2023 Jun 27. PubMed PMID: 37368200.
AÑO: 2024; IF: 2.5
|